Beta Bionics (BBNX) versus Its Rivals Head to Head Comparison

Beta Bionics (NASDAQ:BBNX) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare Beta Bionics to related businesses based on the strength of its valuation, institutional ownership, risk, analyst recommendations, profitability, dividends and earnings.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Beta Bionics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1	4	9	1	2.67
Beta Bionics Competitors	4257	10483	18210	824	2.46

Beta Bionics presently has a consensus target price of $23.69, indicating a potential upside of 41.45%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 25.78%. Given Beta Bionics’ stronger consensus rating and higher possible upside, research analysts plainly believe Beta Bionics is more favorable than its rivals.

Insider & Institutional Ownership

40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 5.3% of Beta Bionics shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Beta Bionics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-65.31%	-27.33%	-24.28%
Beta Bionics Competitors	-278.23%	-150.06%	-21.87%

Valuation & Earnings

This table compares Beta Bionics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Beta Bionics	$100.25 million	-$73.20 million	-9.10
Beta Bionics Competitors	$1.89 billion	$138.79 million	10.75

Beta Bionics’ rivals have higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Beta Bionics has a beta of 3.44, meaning that its share price is 244% more volatile than the S&P 500. Comparatively, Beta Bionics’ rivals have a beta of 2.57, meaning that their average share price is 157% more volatile than the S&P 500.

Summary

Beta Bionics beats its rivals on 7 of the 13 factors compared.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.